AdvaMed Applauds CMS Clarification Regarding Coverage for Insulin Delivery Technologies
WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement today on CMS guidance regarding Medicare Prescription Drug Part D coverage of technologies used for the delivery of insulin for the treatment of diabetes:
“AdvaMed applauds CMS for their guidance confirming that new insulin delivery devices can be covered under the Medicare Part D benefit. This clarification provides an opportunity for America’s seniors with diabetes to have access to new insulin delivery mechanisms that help them manage their disease and prevent complications.
“AdvaMed recently launched a new sector dedicated to advancing policies that will maximize access to life-changing innovations for the more than 30 million people living with diabetes in the U.S. These companies are continually developing innovative technologies to track, diagnose and manage this chronic disease, and timely patient access to these technologies is critical.”